Bristol-Myers Squibb Co
SWB:BRM
Bristol-Myers Squibb Co
SWB:BRM
Price:
51.12
EUR
-1.16%
Market Closed
Market Cap:
€104B
Relative Value
The Relative Value of one
BRM
stock under the Base Case scenario is
57.97
EUR.
Compared to the current market price of 51.12 EUR,
Bristol-Myers Squibb Co
is
Undervalued by 12%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
BRM
Relative Value
Base Case
57.97
EUR
Undervaluation 12%
Multiples Across Competitors
BRM Competitors Multiples
Bristol-Myers Squibb Co Competitors
Bristol-Myers Squibb Co Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| US |
|
Bristol-Myers Squibb Co
SWB:BRM
|
118.9B EUR | 2.5 | 16.9 | 7.1 | 8.8 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
930.7B USD | 14.3 | 45.1 | 30.4 | 32.5 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
581.6B USD | 6.2 | 21.7 | 15.1 | 18.5 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
256.9B CHF | 4.2 | 19.8 | 11.7 | 13.2 | |
| CH |
|
Novartis AG
SIX:NOVN
|
233.7B CHF | 5.3 | 21.5 | 13.3 | 17.1 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
222.2B GBP | 5.1 | 29.1 | 16.1 | 22.7 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
286.1B USD | 4.4 | 15.7 | 9.8 | 11.9 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
218B USD | 94 | -74.6 | 344.9 | 865 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.1T DKK | 3.6 | 10.8 | 8 | 9.4 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
151.1B USD | 2.4 | 19.4 | 7.5 | 10 | |
| UK |
|
GlaxoSmithKline PLC
LSE:GSK
|
83B GBP | 2.5 | 14.5 | 7.4 | 10.5 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
